{"entity":{"id":"zymeworks","kind":"company","name":"Zymeworks","aka":[],"tldr":"Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).","summary":"Zymeworks, based in Vancouver and listed as ZYME, invented zanidatamab, the HER2 bispecific antibody, and a hydrophilic topoisomerase 1 ADC platform. Its Azymetric platform produced zanidatamab, on which it earns royalties, and its own pipeline includes ZW191, a folate receptor alpha ADC that reported a 52 percent response rate in pretreated ovarian and endometrial cancer at AACR 2026, and ZW251 against GPC3. OnCo links it to biliary tract cancer and HER2-positive breast cancer, to the zanidatamab drug record and to Zai Lab. Whether its second-generation ADCs can repeat the success of a bispecific it no longer controls is the open question. Zanidatamab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.zymeworks.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["zanidatamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Vancouver","country":"CA","companyType":"biotech","website":"https://www.zymeworks.com","ticker":"ZYME","investors":[],"funding":[]},"route":"/companies/zymeworks/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"},{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"trial":[{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/"},{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}],"paper":[{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/"}],"company":[{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}]}}